Organogenesis Holdings Inc. (ORGO)
NASDAQ: ORGO · Real-Time Price · USD
5.42
+0.14 (2.65%)
At close: Nov 26, 2025, 4:00 PM EST
5.49
+0.07 (1.29%)
After-hours: Nov 26, 2025, 5:14 PM EST
Organogenesis Holdings Revenue
Organogenesis Holdings had revenue of $150.86M in the quarter ending September 30, 2025, with 30.98% growth. This brings the company's revenue in the last twelve months to $465.22M, up 2.24% year-over-year. In the year 2024, Organogenesis Holdings had annual revenue of $482.04M with 11.29% growth.
Revenue (ttm)
$465.22M
Revenue Growth
+2.24%
P/S Ratio
1.48
Revenue / Employee
$535,349
Employees
869
Market Cap
687.86M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 482.04M | 48.90M | 11.29% |
| Dec 31, 2023 | 433.14M | -17.75M | -3.94% |
| Dec 31, 2022 | 450.89M | -16.47M | -3.52% |
| Dec 31, 2021 | 467.36M | 129.06M | 38.15% |
| Dec 31, 2020 | 338.30M | 77.32M | 29.63% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ORGO News
- 20 days ago - Organogenesis Holdings Inc. (ORGO) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 21 days ago - Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance - GlobeNewsWire
- 24 days ago - Organogenesis Applauds CMS's Significant Step In Payment Reform - GlobeNewsWire
- 27 days ago - Organogenesis Holdings Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Organogenesis Holdings Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ORGO - Business Wire
- 2 months ago - Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025 - GlobeNewsWire
- 2 months ago - Organogenesis: Mixed ReNu Data, But Policy Tailwinds And Growth Remain Bullish - Seeking Alpha
- 2 months ago - Why Is Organogenesis Stock Trading Lower Friday? - Benzinga